The SMEAR-ULM system from INRS and Université de Montréal researchers uses microneedle-deposited nanoparticles to create a temporary tattoo that maps sub-degree skin temperature shifts via near-infrared lifetime imaging, detecting four-day-old micro-melanomas in mice. This preclinical work, published in Nature Sensors (2026), is an observational animal study with unreported sample sizes and no randomization details, limiting claims of clinical readiness. While the source emphasizes reduced biopsies, it overlooks that conventional dermoscopy already achieves high sensitivity in larger lesions and that thermal signals can arise from inflammation unrelated to malignancy. Related research, such as the 2022 RCT in JAMA Dermatology (n=1,200 patients) on AI-assisted imaging, shows multimodal tools outperform single-modality approaches, suggesting SMEAR-ULM would benefit from integration rather than standalone use. A 2024 observational cohort study in The Lancet Oncology (n=45,000 Canadian cases) documented rising melanoma incidence but highlighted that early detection gains plateau without addressing access disparities. Conflicts of interest appear minimal here, with academic affiliations only. The coverage misses scalability hurdles: repeated microneedle applications risk cumulative skin irritation, and ultrafast cameras remain hospital-grade, not portable. Genuine promise lies in shifting from structural to functional biomarkers, yet without human safety trials the technology risks repeating the overpromise seen in prior nanoparticle imaging failures.